MarketInOut Stock Screener Log In | Sign Up

Acumen Pharmaceuticals Inc

IEX • Healthcare • Biotechnology • Quote as of 11/17/2026 15:59
Acumen Pharmaceuticals Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization15.48 mln
Float61.76 mln
Earnings Date03/29/2027

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

1.00
Transformational upside

Relative Strength

56 / 100
Slightly ahead

Debt / Equity

0.76
Moderate leverage

ROE

-152
Deeply negative

ROA

-86.57
Deeply negative

Business Description

Acumen Pharmaceuticals is a clinical-stage company working to develop new treatments for Alzheimer's disease. Its lead drug, Sabirnetug, is designed to target a specific form of amyloid-beta protein believed to drive the disease, and is currently being evaluated in a Phase 2 clinical trial following encouraging Phase 1 results. The company is also working with Halozyme to develop a version of the drug that patients could take by injection under the skin rather than through an IV. Founded in 1996 and based in Newton, Massachusetts, Acumen remains focused on bringing meaningful options to patients affected by Alzheimer's.

Key Fundamentals

EPS-1.55
ROE-152
ROIC-478
ROA-86.57
Interest Cover-24.65
EBITDA, mln-99.53
EV / EBITDA-1.18
EV / EBIT-1.18

Quote Details

Last 0.2301
Change 0.0141 (6.53%)
Open 0.2159
Volume 2,523,329
Turnover 580,618
Average Volume 5,508,554

Financial Ratios

Leverage Ratio2.47
Current Ratio1.89
Price / Book4.90
Price / Tangible Book4.90
Debt / Equity0.76

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price1.00
Short Ratio1.24
Short % of Float9.03

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 0.66% 89 / 100   
1 Month -87.07% 0 / 100   
2 Months -90.83% 0 / 100   
6 Months -89.4% 1 / 100   
1 Year -86.62% 4 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog